UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2021

NEXIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-40045 (Commission File Number) 45-2518457 (IRS Employer Identification No.)

9119 Gaither Road Gaithersburg, Maryland (Address of principal executive offices)

20877 (zip code)

Registrant's telephone number, including area code: (301) 825-9810

	ck the appropriate box below if the Form 8-K filing is intwing provisions:	rended to simultaneously satisfy the fi	ling obligation of the registrant under any of the		
	Written communications pursuant to Rule 425 under th	e Securities Act (17 CFR 230.425)			
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule	14d-2(b) under the Exchange Act (17	CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				
Securities registered pursuant to Section 12(b) of the Act:					
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered		
Co	Title of each class ommon Stock, \$0.0001 par value per share				
Indic		Symbol(s) NEXI growth company as defined in Rule 4	on which registered The Nasdaq Stock Market LLC		
Indic or R	ommon Stock, \$0.0001 par value per share cate by check mark whether the registrant is an emerging	Symbol(s) NEXI growth company as defined in Rule 4	on which registered The Nasdaq Stock Market LLC		

Item 2.02 Results of Operations and Financial Condition.

On August 9, 2021, NexImmune, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2021 and providing business highlights. The full text of the press release is incorporated by reference herein and furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On August 9, 2021 the Company issued a press release announcing its collaboration with Yale University's Department of Immunobiology, which will focus on the use of the Company's direct injection, artificial antigen presenting cells with regards to the regulation of autoimmune diabetes. The full text of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release announcing the Company's financial results for the second quarter ended June 30, 2021, dated August 9, 2021.
99.2	Press release announcing the Company's collaboration with Yale University's Department of Immunobiology
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NEXIMMUNE, INC.

By: /s/ John Trainer

John Trainer Chief Financial Officer

Date: August 9, 2021



NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates

- Announcing first solid tumor indication in HPV associated-malignancies NEXI-003
- Advancing two lead product candidates in Phase 1/2 clinical trials
- Additional clinical and preclinical data anticipated in the second half of 2021

GAITHERSBURG, Md., August 9, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for the second quarter of 2021.

"The first half of the year was a very productive period for the company. We are focused on completing enrollment in our Phase I/II clinical trials for NEXI-001 and NEXI-002 and expect to present additional clinical data for each during scientific conferences toward the end of this year," said Scott Carmer, Chief Executive Officer. "We are also excited to announce our first indication in solid tumors and expect to submit our IND for HPV-associated malignancies in the second quarter of 2022. Additionally, we've initiated IND-enabling pre-clinical experiments that will be the basis for multiple IND submissions in support of our injectable nanoparticle (AIM INJ). This progress highlights the promise of our AIM platform across disease areas and delivery modalities, and we look forward to providing further updates on these important programs later this year."

Select 2Q 2021 Clinical and Business Highlights

Clinical and Preclinical Updates

NEXI-001

- Abstract presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting in June 2021 highlights safety, tolerability, immune responses and early clinical activity in all patients evaluated
- Dose Level 2 (single infusion of 200M cells/month x two cycles) is fully enrolled
- Dose Level 3 (single infusion of 200M cells/week for three weeks x two cycles) is enrolling
- Treatment-related adverse events, including infusion reactions, GVHD, CRS, and neurotoxicity (ICANS), have not been observed in patients who received NEXI-001 at Dose Level 1 and Dose Level 2, either as single or repeat infusions
- Further data expected to be announced during the American Society of Hematology (ASH) Annual Meeting in December 2021

NEXI-002

- Abstract presented at European Hematology Association Annual Meeting in May 2021 highlights safety, tolerability and immune responses in all patients evaluated
- Safety cohort completed and expansion phase is enrolling
- Treatment-related adverse events, including infusion reactions, CRS, and neurotoxicity (ICANS), have not been observed in patients who received NEXI-002
- Further data expected to be announced during the American Society of Hematology (ASH) Annual Meeting in December 2021

NEXI-003

- · First solid tumor clinical trial for multi-antigen autologous AIM ACT product will target HPV-associated malignancies
- Preclinical data validating the selection of multiple immunogenic HPV antigen peptides expected to be announced during the Society for Immunotherapy of Cancer's Annual Meeting (SITC 2021) in November 2021
- Investigational new drug (IND) submission planned for 2Q 2022

Other R&D

- IND enabling preclinical studies for the AIM INJ platform continue; abstract presentations planned for SITC 2021 in November 2021
- First collaboration in autoimmune diseases announced with Yale University to evaluate AIM INJ nanoparticles in Type 1 diabetes

Business Updates

- Announced formation of the company's Scientific Advisory Board
- · Announced the appointments of Dr. Jack Ragheb, SVP, Translational Medicine, and Matthew Schiller, Head of Business Development

Select 2Q 2021 Financial Highlights

Cash, cash equivalents and marketable securities for the company as of June 30, 2021 were \$102.8M compared to \$118.1M for quarter ending March 31, 2021. Based upon current operating plans, NexImmune expects that its existing cash, cash equivalents and marketable securities will enable the company to fund its operating and capital expenditure requirements through the third quarter of 2022.

Research and development expenses were \$8.1M in the second quarter of 2021, compared to \$4.2M for the same period in the prior year. The increase in R&D expenses was mainly attributable to costs for the two clinical trials, as well as personnel-related expenses driven by increased headcount-

General and administrative expenses were \$4.0M, compared to \$2.6M for the same period the prior year. The increase was due primarily to increases in headcount and fees related to professional and consulting services.

Net loss, according to generally accepted accounting principles in the U.S. (GAAP), was \$12.2M for the quarter, or a basic and diluted GAAP loss per share of \$0.54. This compared to a net loss of \$6.9M, or a basic and diluted GAAP loss per share of \$6.17, for the same period the prior year.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM^{TM}) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to 3 or more prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

For more information, visit www.neximmune.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our results of operations for the six months ended June 30, 2021; the sufficiency of the Company's current cash, cash equivalents and marketable securities to fund its planned operations through the third quarter of 2022; our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001, NEXI-002 and NEXI-003; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

NEXIMMUNE, INC.

BALANCE SHEETS

Circertor Circertor Control		June 30, 2021 (unaudited)	December 31, 2020	
Cash and cash equivalents \$ 6,301,000 Marketable securities 36,705,000 Restricted cash 67,000 Prepaid expenses and other current assets 111,003 3,203,808 Tope yand equipment, net 4,148,607 2,805,800 Chrer non-current assets 513,307 30,300 Total assets 513,000 31,000 LIABILITES, REDEEMABLE CONVERTIBLE PREFERENT STOCK AND STOCKHOLTES TEVETY 52,000 2,000,000 CIVEN Counts payable 2,469,000 2,000,000 Accrued expenses 2,469,000 3,000,000 Derivative liabilities 36,30 3,000,000 Convertible notes issued to related parties 4,000,000 4,000,000 Convertible notes 2,499,100 2,000,000 Total current liabilities 3,000,000 4,000,000 Deferred cent, net of current portion 5,000,000 2,000,000 Other current liabilities 5,000,000 2,000,000 Redeemable convertible preferred stock, \$0,0001 par value, no shares outstanding as of June 30,000 5,000,000 Series A.2 Redeemable Convertible Preferred Stock, \$0,0001 par va	ASSETS	(
Maketable securities 38,997,60 — Restricted cash 67,500 5,203,20 Prepaid expenses and other current assets 11,100,300 3,203,20 Total current assets 5,303 23,303 Total assets 5,303 23,303 Total assets 5,303 23,303 Colspan="2">Construction assets 5,200 2,200,200 Colspan="2">Construction assets 2,200,200 2,200,200 Colspan="2">Colspan="2">Construction in the colspan="2">Co	Current assets:			
Restricted cash 6,75,00 32,717 32,385,88 Total current assets 11,190,393 2,382,68 Properly and equipment, net 4,148,875 2,382,60 Other non-current assets 51,302,01 31,302,00 Total assets 515,302,01 31,302,00 LIABLITIES, REDEFMABLE CONVERTIBLE PREFERENT STOCK AND STOCK HUBBERS 52,160,00 52,700,10 Accounts pash 2,469,00 52,700,10 Accounted expenses 2,469,00 52,000,20 Derivative liabilities 43,00 43,00 Convertible notes issued to related parties 45,00 42,00 Other current liabilities 45,00 43,00 43,00 Convertible notes issued to related parties 5,432,00 43,00 43,00 43,00 Other current liabilities 5,433,00 7,00 43,00	Cash and cash equivalents	\$ 63,816,106	\$ 5,031,079	
Prepaid expenses and other current assets 8,327,117 3,293,685 Total current assets 11,109,087 8,302,437 Other on-current assets 53,373 23,373 Total assets 53,373 3,130,303 LIABILITIES, REDEEMABLE CONVERTIBLE PREFERED STOCK AND STOCKHOLDER'S EUGHT CHORNIEL STOCK AND STOCK	Marketable securities	38,979,670	_	
Total current assets 111,190,39 8,392,437 Property and equipmen, net 4,148,65 2,855,260 Other non-current assets 51,373 23,373 Total assets 51,530,261 \$1,300,000 LIABILITIES, REDEMABLE CONVERTIBLE PREFERED STOCK AND STOCKHOLDERS' UNIVERSIBLE PREFERED STOCK AND STOCKHOLDERS' UNIVERS' UNIVERSIBLE PREFERED STOCK AND STOCKHOLDERS' UNIVERS' UNIVERS		67,500	67,500	
Property and equipment, net 4,184,87 2,885,260 Other non-current assets 53,37 10,303,20 33,37 TAG assets 15,392,61 15,392,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 15,302,61 25,402,02 26,002,02	Prepaid expenses and other current assets	8,327,117	3,293,858	
Other non-current assets 53,30 23,30 Total sests 51,30,20 \$1,30,00 LABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDER'S EQUITY Unrent liabilities: Accound spayable \$1,609,00 \$2,600,102 Accounds payable \$4,609,00 \$6,000,00 Cherivative liabilities 843,619 843,619 Convertible notes issued to related parties \$4,000 1,70,325 Convertible notes issued to related parties \$4,000 1,70,325 Convertible notes issued to related parties \$4,000 4,000 Convertible notes \$4,000 4,000 Deferred rent, net of current portion \$4,000 4,000 Other non-current liabilities \$4,000 4,000 Redemand contriguent perferred stock	Total current assets	111,190,393	8,392,437	
Total assets	Property and equipment, net	4,148,875	2,885,260	
Current liabilities	Other non-current assets	53,373	23,373	
DEFICITY Inimities:	Total assets	\$115,392,641	\$ 11,301,070	
Accounts payable \$2,169,600 \$2,760,129 Accrued expenses 2,469,002 7,002,002 Derivative liabilities 6 1,702,358 Other current liabilities 843,619 7,324,267 Convertible notes issued to related parties 5 7,324,267 Convertible notes 5,483,221 11,793,397 Total current portion 5,483,221 20,502,698 Other non-current liabilities 5,483,221 2,705,262 Other non-current liabilities 5,483,221 2,705,262 Referender ent, net of current portion 5,483,221 2,705,262 Other non-current liabilities 5,483,221 2,705,262 Referendber convertible preferred stock 5,483,221 2,705,262 Series A Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 3,504,745 Series A.2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 4,505,605 Series A.2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 4,768,605 Series A.3 Redeemable Convertible Preferred Stock, \$0,00001 par value, no shares outstanding as of Ju				
Accrued expenses 2,469,942 2,600,027 Derivative liability — 1,702,359 Other current liabilities 843,619 843,619 Convertible notes issued to related parties — 7,324,267 Convertible notes — 1,793,397 Total current portion — 23,529 Other non-current liabilities 5,483,221 27,055,262 Commitments and contingencies — 4,935 Redeemable convertible preferred stock — 4,935 Series A Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 — 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 — 7,685,665 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 — 7,685,665 Series A-3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 — 7,685,665 Series A-3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 — 7,685,665 Series A-3 Redeemable Convertible Preferred Stock <	Current liabilities:			
Derivative liability In 7,02,359 Other current liabilities 83,619 834,619 Convertible notes issued to related parties - 7,324,267 Convertible notes - 1,793,397 Total current liabilities 5,883,221 27,026,798 Defer on current liabilities - 4,935 Other non-current liabilities - 4,935 Total liabilities - 4,935 Redeemable convertible preferred stock - 4,935 Series A Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 - 35,047,435 Series A Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 - 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 - 7,685,685 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 - 7,685,685 Series A-3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 - 7,685,685 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstan	Accounts payable	\$ 2,169,660	\$ 2,760,129	
Other current liabilities 843,619 843,619 Convertible notes issued to related parties — 7,324,267 Convertible notes — 11,733,397 Total current liabilities 5,483,221 27,026,788 Deferred rent, net of current portion — 4,935 Other one-current liabilities — 5,832,22 27,055,262 Total liabilities — 5,832,21 27,055,262 Redeemable convertible preferred stock Series A Redeemable Convertible Preferred Stock, \$0,001 par value, no shares outstanding as of June 30, 2021 — 5,842,314,789 as of December 31, 2020. — 5,842,314,789 as of December 31, 2020. — 6,835,842 — 6,835,842 — 6,835,842 — 7,685,865 —	Accrued expenses	2,469,942	2,603,027	
Convertible notes issued to related parties 7,324,267 Convertible notes 2 11,793,37 Total current liabilities 5,483,21 27,026,798 Deferred rent, net of current portion 23,529 23,529 Other non-current liabilities 5,483,21 27,055,026 Commitments and contingencies Redeemable convertible preferred stock Series A Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 201 4 Liquidation value of \$8,683,746 as of December 31, 2020. 5 7,685,685 Series A-3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 202 4 1 Liquidation value of \$1,699,176 as of December 31, 2020. 5 6 5,865,685 Series A-3 Redeemable Convertible Preferred Stock 5 6 5,862,049	Derivative liability	_	1,702,359	
Convertible notes — 11,793,377 Total current liabilities 5,483,211 27,026,798 Defer cle rent, net of current portion — 2,835,29 Other non-current liabilities — 5,483,21 2,705,262 Total liabilities 5,483,21 2,705,262 Commitments and contingencies Redeemable Convertible Preferred Stock Series A R Redeemable Convertible Preferred Stock, 50,0001 par value, no shares outstanding as of June 30, 2011 — 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, 50,0001 par value, no shares outstanding as of June 30, 2012 — 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, 50,0001 par value, no shares outstanding as of June 30, 2012 — 7,685,865 Series A-3 Redeemable Convertible Preferred Stock, 50,0001 par value, no shares outstanding as of June 30, 2012 — 7,685,865 Series A-3 Redeemable Convertible Preferred Stock, 50,0001 par value, no shares outstanding as of June 30, 2012 — 7,685,865 Series A-3 Redeemable Convertible Preferred Stock, 50,0001 par value, no shares outstanding as of June 30, 2012 — 7,685,865 Series A-3 Redeemable convertible preferred Stock, 50,0001 par value, no shares outstanding as of June 30, 2012 — 7,685,865 <td c<="" td=""><td></td><td>843,619</td><td>843,619</td></td>	<td></td> <td>843,619</td> <td>843,619</td>		843,619	843,619
Total current liabilities 5,483,201 27,026,798 Deferred rent, net of current portion 23,529 Other non-current liabilities 5,483,201 4,935 Total liabilities 5,483,201 27,055,262 Total liabilities 5,483,201 27,055,262 Redeemable convertible preferred stock Series A Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 36,047,435 Series A-3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 36,047,435 Series A-3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 36,047,435 Liquidation value of \$8,683,746 as of December 31, 2020. — 7,685,865 Series A-3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares sized and outstanding as of June 30, 2021 20 35,020,495 Total redeemable convertible Preferred Stock	Convertible notes issued to related parties	_		
Deferred rent, net of current portion	Convertible notes		11,793,397	
Other non-current liabilities — 4,935 Total liabilities 5,483,221 27,055,262 Commitments and contingencies — 8,243,214,200 — 8,243,214,200 Series A Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of \$42,314,789 as of December 31, 2020. — 8,244,314,789 — 3,5047,435 Series A P.2 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. — 7,685,865 Series A 3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. — 7,685,865 Series A 3 Redeemable Convertible Preferred Stock, \$0,0001 par value, no shares outstanding as of June 30, 2021 and 25,069,9176 as of December 31, 2020. — 8,262,268 — 8,26	Total current liabilities	5,483,221	27,026,798	
Total liabilities 5,483,221 27,055,262 Commitments and contingencies Redeemable convertible preferred stock Series A Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of \$42,314,789 as of December 31, 2020. — 35,047,435 Series A-2 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. — 7,685,865 Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 21,209,734 shares issued and outstanding as of December 31, 2020. — 7,685,865 Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 31,699,176 as of December 31, 2020. — 10,887,449 Total redeemable convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of December 31, 2020. — 10,887,449 Total redeemable convertible Preferred Stock, \$0.0001 par value, no shares issued and outstanding as of December 31, 2020. — 10,887,449 Total redeemable convertible preferred stock — 53,620,749 Stockholders' equity (deficit) 2,263 126	Deferred rent, net of current portion		23,529	
Redeemable convertible preferred stock Series A Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of \$42,314,789 as of December 31, 2020. Series A-2 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of \$8,683,746 as of December 31, 2020. Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Total redeemable convertible preferred stock June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional paid-in-capital Accumulated other comprehensive loss Cumulated other comprehensive loss Total stockholders' equity (deficit) Total stockholders' equity (deficit) Total stockholders' equity (deficit) Total stockholders' equity (deficit)	Other non-current liabilities	_	4,935	
Redeemable convertible preferred stock Series A Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of \$42,314,789 as of December 31, 2020. Series A-2 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of \$8,683,746 as of December 31, 2020. Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Total redeemable convertible preferred stock Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional paid-in-capital Accumulated other comprehensive loss Common Stock stockholders' equity (deficit) Total stockholders' equity (deficit) Total stockholders' equity (deficit) Total stockholders' equity (deficit) Total stockholders' equity (deficit)	Total liabilities	5,483,221	27,055,262	
Series A Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of \$42,314,789 as of December 31, 2020. Series A-2 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of \$8,683,746 as of December 31, 2020. Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Total redeemable convertible preferred stock Stockholders' equity (deficit) Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional paid-in-capital 207,480,819 8,206,938 Accumulated other comprehensive loss (2,917) — Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)	Commitments and contingencies			
and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of \$42,314,789 as of December 31, 2020. Series A-2 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of \$8,683,746 as of December 31, 2020. Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Total redeemable convertible preferred stock Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional paid-in-capital Accumulated other comprehensive loss Accumulated deficit Total stockholders' equity (deficit)	Redeemable convertible preferred stock			
Series A-2 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of \$8,683,746 as of December 31, 2020. Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Total redeemable convertible preferred stock Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional paid-in-capital 207,480,819 8,206,938 Accumulated other comprehensive loss (2,917) — Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)	and 121,735,303 shares authorized, issued and outstanding as of December 31, 2020. Liquidation value of			
and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020. Liquidation value of \$8,683,746 as of December 31, 2020. Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Total redeemable convertible preferred stock Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional paid-in-capital Accumulated other comprehensive loss Common Stock sholders' equity (deficit) Total stockholders' equity (deficit) 109,909,420 109,874,941)		_	35,047,435	
Series A-3 Redeemable Convertible Preferred Stock, \$0.0001 par value, no shares outstanding as of June 30, 2021 and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Total redeemable convertible preferred stock Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional paid-in-capital Accumulated other comprehensive loss Accumulated deficit Total stockholders' equity (deficit) 109,909,420 (69,374,941)	and 28,384,899 shares authorized, 22,047,361 shares issued and outstanding as of December 31, 2020.		5 00 5 00 5	
and 34,061,879 shares authorized, 31,209,734 shares issued and outstanding as of December 31, 2020. Liquidation value of \$11,699,176 as of December 31, 2020. Total redeemable convertible preferred stock Stockholders' equity (deficit) Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. Additional paid-in-capital Accumulated other comprehensive loss Accumulated deficit Total stockholders' equity (deficit) Total stockholders' equity (deficit) 109,909,420 10,887,449 53,620,749 22,63 126 207,480,819 8,206,938 (2,917) Accumulated deficit 109,909,420 (69,374,941)			7,685,865	
Liquidation value of \$11,699,176 as of December 31, 2020. — 10,887,449 Total redeemable convertible preferred stock — 53,620,749 Stockholders' equity (deficit) Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. 2,263 126 Additional paid-in-capital Accumulated other comprehensive loss 207,480,819 8,206,938 Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)	· · · · · · · · · · · · · · · · · · ·			
Total redeemable convertible preferred stock — 53,620,749 Stockholders' equity (deficit) Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. 2,263 126 Additional paid-in-capital 207,480,819 8,206,938 Accumulated other comprehensive loss (2,917) — Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)			10 007 440	
Stockholders' equity (deficit) Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. 2,263 126 Additional paid-in-capital 207,480,819 8,206,938 Accumulated other comprehensive loss (2,917) — Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)	1			
Common Stock, \$0.0001 par value, 250,000,000 shares authorized, 22,628,007 issued and outstanding as of June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. 2,263 126 Additional paid-in-capital 207,480,819 8,206,938 Accumulated other comprehensive loss (2,917) — Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)	-	_	53,620,749	
June 30, 2021 and 1,256,609 shares issued and outstanding as of December 31, 2020. 2,263 126 Additional paid-in-capital 207,480,819 8,206,938 Accumulated other comprehensive loss (2,917) — Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)				
Additional paid-in-capital 207,480,819 8,206,938 Accumulated other comprehensive loss (2,917) — Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)		2 263	126	
Accumulated other comprehensive loss (2,917) — Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)				
Accumulated deficit (97,570,745) (77,582,005) Total stockholders' equity (deficit) 109,909,420 (69,374,941)				
Total stockholders' equity (deficit) 109,909,420 (69,374,941)	•		(77,582,005)	
TOTAL DADDINES, PEDERMANIE CONVENINIE DEFERENCIA STOCK AND STOCKNOTORYS' FORMAT TOPOCHET STOCK AND STOCKNOTORYS' FORMAT FORMAT FORMAT FORMAT FORMAT FORMAT FORMAT FORMAT FO	Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	\$115,392,641	\$ 11,301,070	

NEXIMMUNE, INC.

STATEMENTS OF OPERATIONS (unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
_	2021	2020	2021	2020
Revenue	\$ —	\$ —	\$ —	\$ —
Operating expenses:				
Research and development	8,124,973	4,209,261	14,137,581	8,481,428
General and administrative	4,038,050	2,565,402	8,095,642	4,653,803
Total operating expenses	12,163,023	6,774,663	22,233,223	13,135,231
Loss from operations	(12,163,023)	(6,774,663)	(22,233,223)	(13,135,231)
Other (expense) income:				
Interest income	6,851	1,184	10,464	19,868
Interest expense	(101)	(183,682)	(904,220)	(184,671)
Change in fair value of derivative liability	_	_	2,424,877	_
Other (expense) income	(25,974)	26,636	(26,696)	54,001
Other (expense) income	(19,224)	(155,862)	1,504,425	(110,802)
Net Loss	\$(12,182,247)	\$(6,930,525)	\$(20,728,798)	\$(13,246,033)
Accumulated dividends on Redeemable Convertible Preferred Stock	_	(815,816)	(377,562)	\$ (1,631,632)
Net loss attributable to common stockholders	\$(12,182,247)	\$(7,746,341)	\$(21,106,360)	\$(14,877,665)
Basic and diluted net loss attributable to common stockholders per common share	\$ (0.54)	\$ (6.17)	\$ (1.20)	\$ (11.86)
Basic and diluted weighted-average number of common shares outstanding	22,608,866	1,254,681	17,648,551	1,254,681

STATEMENTS OF COMPREHENSIVE LOSS (unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2021	2020	2021	2020
Net loss	\$(12,182,247)	\$(6,930,525)	\$(20,728,798)	\$(13,246,033)
Other comprehensive loss:				
Unrealized (loss) gain on available-for-sale marketable securities, net of tax	(2,917)		(2,917)	(506)
Comprehensive loss	\$(12,185,164)	\$(6,930,525)	\$(20,731,715)	\$(13,246,539)

Contacts

Investors:

Chad Rubin, SVP Corporate Affairs NexImmune, Inc. 646.319.3261 crubin@neximmune.com

Media:

Mike Beyer Sam Brown Inc. Healthcare Communications 312.961.2502 mikebeyer@sambrown.com



NexImmune to Explore the Use of AIMTM Direct Injection Technology in Type 1 Diabetes

GAITHERSBURG, MD – August 9, 2021 – NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Yale University's Department of Immunobiology. The collaboration will focus on the use of NexImmune's direct injection, artificial antigen presenting cells (AIM INJ) with regards to the regulation of autoimmune diabetes (Type 1 diabetes). Dr. Kevan Herold, Deputy Director of Yale Center for Clinical Investigation and Co-Director of the Yale Diabetes Center will be the principal investigator.

"We are excited to enter into this collaboration that will explore our next-generation, direct-injectable artificial antigen presenting cell platform for autoimmune diseases," said Dr. Jerry Zeldis, Executive Vice President, R&D of NexImmune. "Our goal with Dr. Herold is to advance novel treatments that could potentially reverse the course and prevent type 1 diabetes by targeting the auto-reactive T cells that cause this disease."

"By directly targeting the auto-reactive T cells that are known to be a mediator of pancreatic beta cell destruction, we can potentially develop a transformative therapy for patients suffering with autoimmune diabetes. Working with NexImmune allows us to explore a very compelling technology to impact this life-long and difficult to control disease" stated Dr. Herold.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune's approach is a proprietary Artificial Immune Modulation (AIM TM) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

NexImmune's two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

For more information, visit www.neximmune.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning our planned and ongoing clinical studies for the Company's product candidates, including NEXI-001 and NEXI-002; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior preclinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission ("SEC") on March 31, 2021, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly upda

###

Contacts

Investors:

Chad Rubin, SVP Corporate Affairs NexImmune, Inc. 646.319.3261 <u>crubin@neximmune.com</u>